 |
Top 9 Liver Disease treatment startups in USA
Oct 12, 2024 | By Jason Kwon | 19 |
1
Funding: $3.9B
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
2
Funding: $1.6B
The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease.
The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease.
3
Funding: $951.1M
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
4
Funding: $497M
Mirum Pharmaceuticals develops drugs for rare cholestatic liver diseases.
Mirum Pharmaceuticals develops drugs for rare cholestatic liver diseases.
5
Funding: $442.6M
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
6
Funding: $173M
Metacrine is an emerging biotech company focused on developing best-in-class therapies to benefit patients with liver, gastrointestinal, and metabolic diseases.
Metacrine is an emerging biotech company focused on developing best-in-class therapies to benefit patients with liver, gastrointestinal, and metabolic diseases.
7
Funding: $39M
Ocelot Bio brings new treatment options to patients with severe liver disease.
Ocelot Bio brings new treatment options to patients with severe liver disease.
8
Funding: $35M
Inipharm is building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease.
Inipharm is building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease.
9
Funding: $3M
In Diagnostics is developing next generation disposable lab-quality spectrophotometer that rely on digital microchips to analyze biological samples.
In Diagnostics is developing next generation disposable lab-quality spectrophotometer that rely on digital microchips to analyze biological samples.
